8-K: Imunon Appoints Former CFO Jeffrey Church as Interim Finance Chief
Management Change
Imunon, Inc. announced the resignation of interim CFO Kimberly Graper and the appointment of former Executive Vice President and CFO Jeffrey Church as her interim successor, effective January 14, 2026.
Summary
- Interim Chief Financial Officer Kimberly Graper will resign from her role at Imunon, Inc. effective January 14, 2026.
- Ms. Graper's departure is to pursue another career opportunity and is without any disagreements with management.
- Jeffrey Church has been appointed as the Company's interim Chief Financial Officer, effective January 14, 2026.
- Mr. Church will also serve as the principal financial officer and principal accounting officer.
- Mr. Church previously served as the Company's Executive Vice President, Chief Financial Officer, and Corporate Secretary before retiring in May 2024 and continuing in a consulting role.
- The Company and Mr. Church amended their Consulting Agreement, effective January 14, 2026, to pay him a monthly retainer of $30,000, plus $250 per hour for services exceeding 40 hours per month.
Sentiment
Score: 6
Explanation: The sentiment is slightly positive due to the amicable departure of the interim CFO and the immediate appointment of a highly experienced former CFO, ensuring continuity and stability in a key leadership role. This minimizes potential disruption.
Positives
- Ms. Graper's departure is amicable, "without any disagreements with management," indicating a smooth transition.
- The company has secured an experienced former CFO, Jeffrey Church, to step in as interim CFO, ensuring continuity and leveraging his deep institutional knowledge.
- Mr. Church's extensive prior experience with Imunon (since 2010) and other life science companies provides stability during the transition.
Negatives
- The departure of an interim CFO, even if amicable, can introduce a period of uncertainty until a permanent replacement is found.
Risks
- Potential for disruption during the transition period as a new permanent CFO is sought and integrated.
- Reliance on an interim executive, even an experienced one, may signal a lack of long-term financial leadership stability.
Future Outlook
The company anticipates a smooth management transition following the interim CFO appointment, leveraging the extensive prior experience of Mr. Church.
Management Comments
- We thank Kimberly for her contributions over the past three years, and particularly in her recent Interim role.
- We wish Kimberly the very best in her future endeavors.
Industry Context
In the biotechnology sector, stability in financial leadership is crucial for investor confidence, especially for companies navigating clinical development and potential commercialization. The appointment of a former, experienced CFO as interim provides a degree of stability during a transition period, which is generally viewed favorably compared to bringing in an entirely new, external interim executive.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Interim Chief Financial Officer | Kimberly Graper | January 14, 2026 | Resignation to pursue an attractive career opportunity. | |
| Interim Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer | Jeffrey Church | January 14, 2026 | Appointment following the resignation of the previous interim CFO. |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Amendment to Consulting Agreement | The Consulting Agreement with Jeffrey Church was amended to extend the consulting period and adjust compensation to a monthly retainer of $30,000, plus $250 per hour for services exceeding 40 hours per month. | January 14, 2026 | Ensures continued financial leadership and expertise from a former executive during the interim period, providing stability. |
Related Party Transactions
- Amendment to the Consulting Agreement with Jeffrey Church, a former Executive Vice President, Chief Financial Officer, and Corporate Secretary, for his services as interim CFO.
Stakeholder Impact
- Shareholders: The appointment of an experienced former CFO as interim provides stability and continuity in financial leadership, potentially mitigating concerns about executive transitions.
- Employees: A smooth leadership transition can maintain morale and operational focus.
- Creditors: Continuity in financial reporting and management can reassure creditors.
Next Steps
- Smooth management transition for the interim CFO role.
- Potential search for a permanent Chief Financial Officer.
Key Dates
| Date | Description |
|---|---|
| 1979 | Jeffrey Church started his career with Price Waterhouse. |
| 1986 | Jeffrey Church concluded his tenure with Price Waterhouse. |
| 1998 | Jeffrey Church began serving as Vice President, CFO, and Corporate Secretary for GenVec, Inc. |
| 2006 | Jeffrey Church concluded his tenure with GenVec, Inc. and began serving as Vice President, Chief Financial Officer, and Corporate Secretary for Novavax, Inc. |
| 2007 | Jeffrey Church concluded his tenure with Novavax, Inc. and began serving as Chief Financial Officer and Corporate Secretary of Alba Therapeutics Corporation. |
| 2010 | Jeffrey Church concluded his tenure with Alba Therapeutics Corporation and joined Imunon, Inc. as Vice President, Chief Financial Officer, and Corporate Secretary. |
| July 2011 | Jeffrey Church was appointed as Senior Vice President, Corporate Strategy and Investor Relations at Imunon, Inc. |
| July 2013 | Jeffrey Church was reappointed as Senior Vice President and Chief Financial Officer at Imunon, Inc. |
| December 2018 | Jeffrey Church was promoted to Executive Vice President at Imunon, Inc. |
| May 17, 2024 | Imunon, Inc. and Mr. Church entered into a retirement and consulting agreement. |
| May 20, 2024 | Current Report on Form 8-K filed regarding the retirement and consulting agreement. |
| June 1, 2024 | Jeffrey Church retired from his roles as Executive Vice President, Chief Financial Officer, and Corporate Secretary of Imunon, Inc. |
| December 31, 2024 | Original term end date for Jeffrey Church's consulting services. |
| January 7, 2026 | Date of report and announcement of Kimberly Graper's resignation and Jeffrey Church's appointment. |
| January 14, 2026 | Effective date of Kimberly Graper's resignation and Jeffrey Church's appointment as interim CFO. |
Recommendation
holdThis filing primarily details a routine management transition with the interim CFO resigning and a highly experienced former CFO stepping in. While the departure of an interim executive can sometimes signal instability, the immediate appointment of a known and experienced individual like Jeffrey Church mitigates potential negative impacts. There are no new financial results, strategic shifts, or significant risks disclosed that would warrant a change in investment thesis. Therefore, a 'hold' recommendation is appropriate, maintaining current positions while monitoring for the appointment of a permanent CFO and future operational updates.
Keywords
Imunon, IMNN, CFO, Chief Financial Officer, Management Change, Executive Appointment, Biotechnology, Corporate Governance, SEC Filing, 8-K
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.